ASTRAZEN - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 2.8
| Stock Code | ASTRAZEN | Market Cap | 20,532 Cr. | Current Price | 8,213 ₹ | High / Low | 10,691 ₹ |
| Stock P/E | 98.7 | Book Value | 320 ₹ | Dividend Yield | 0.39 % | ROCE | 33.4 % |
| ROE | 23.6 % | Face Value | 2.00 ₹ | DMA 50 | 8,440 ₹ | DMA 200 | 8,570 ₹ |
| Chg in FII Hold | 0.07 % | Chg in DII Hold | 0.24 % | PAT Qtr | 31.6 Cr. | PAT Prev Qtr | 58.1 Cr. |
| RSI | 43.6 | MACD | 12.1 | Volume | 11,763 | Avg Vol 1Wk | 6,780 |
| Low price | 7,552 ₹ | High price | 10,691 ₹ | PEG Ratio | 2.28 | Debt to equity | 0.04 |
| 52w Index | 21.1 % | Qtr Profit Var | -42.3 % | EPS | 80.4 ₹ | Industry PE | 30.1 |
📉 ASTRAZEN is trading at ₹8,213, below both its 50 DMA (₹8,440) and 200 DMA (₹8,570), signaling weakness. RSI at 43.6 indicates bearish momentum, while MACD at 12.1 shows mild positive divergence but lacks strong confirmation. Bollinger Bands suggest price consolidation near the lower band. Volume (11,763) is slightly above the 1-week average (6,780), showing moderate activity but not strong conviction.
🔑 Short-term momentum signals: Weak trend with support near ₹7,552 and resistance around ₹8,440–₹8,570. Entry zone lies closer to ₹7,600–₹7,700 if support holds. Exit zone should be considered near ₹8,400–₹8,600 unless momentum strengthens. The stock is in a consolidation phase with bearish bias.
✅ Positive
- Low debt-to-equity ratio (0.04) ensures balance sheet strength.
- EPS of ₹80.4 is strong relative to peers.
- ROCE at 33.4% and ROE at 23.6% reflect efficient capital use.
⚠️ Limitation
- High P/E of 98.7 vs industry average of 30.1 indicates overvaluation.
- Quarterly profit dropped -42.3%, showing earnings pressure.
- PEG ratio of 2.28 suggests expensive growth prospects.
📉 Company Negative News
- Sharp decline in quarterly PAT (₹31.6 Cr vs ₹58.1 Cr).
- Weak 52-week performance at 21.1% index level.
📊 Company Positive News
- Stable institutional holding with slight increase in DII (+0.24%).
- Consistent dividend yield (0.39%) supports investor confidence.
🏭 Industry
- Industry P/E at 30.1 highlights sector valuation gap.
- Healthcare sector remains defensive but faces margin pressures.
📝 Conclusion
ASTRAZEN shows weak technical momentum with price below key moving averages and RSI in bearish territory. Fundamentals remain strong, but overvaluation and profit decline weigh heavily. Best suited for cautious monitoring with entry near support zones and strict stop-loss discipline.
Would you like me to extend this into a modular swing-trade HTML report with sector overlays and peer benchmarking, so you can compare ASTRAZEN against other pharma stocks in your workflow library?